#United States #Class Action #Kessler Topaz #Radnor #DexCom

Important Reminder for DexCom Investors

As December 26, 2025, approaches, investors in DexCom, Inc. are being urged to take action regarding potential claims for securities fraud. The law firm Kessler Topaz Meltzer & Check, LLP has filed a class action lawsuit against DexCom, accusing the company of making misleading statements about its products during a specific time frame.

Overview of the Class Action

This class action lawsuit targets those who held DexCom securities between January 8, 2024, and September 17, 2025. These claims stem from the allegation that DexCom's management knowingly issued materially false statements that influenced stock prices and misled investors. The firm's announcement introduces critical deadlines for affected parties, emphasizing that interested investors must seek inclusion in the lead plaintiff process by December 26, or risk becoming non-participants in the class action suit.

Allegations Against DexCom

The lawsuit highlights several significant allegations:
1. Unauthorized Design Changes: DexCom allegedly made unauthorized adjustments to its G6 and G7 continuous glucose monitoring devices. These changes purportedly compromised the reliability and safety of the products.
2. Health Risks: The modifications made to the devices may have posed serious health risks to users who depended on them for accurate glucose monitoring.
3. Misleading Enhancements: DexCom's claims regarding enhancements to the G7 device’s functionality are claimed to have been overstated, obscuring the real issues surrounding product reliability.
4. Regulatory Scrutiny: The alleged misconduct would likely result in increased scrutiny from regulators, leaving DexCom vulnerable to potential legal ramifications.
5. False Public Statements: Throughout the class period, the public statements made by DexCom were allegedly false and misleading, undermining investor confidence and leading to significant financial losses.

The Lead Plaintiff Process

Investors wishing to actively participate can potentially serve as lead plaintiffs. This role is essential because the lead plaintiff represents all class members in directing the litigation. Typically, the lead plaintiff is the individual or group with the most substantial financial interest in the case, providing a voice for those affected. However, those who opt not to assume this role can still remain part of the class and benefit from any eventual recovery from the suit.

Kessler Topaz encourages all DexCom investors who believe they have suffered losses to reach out for further information and guidance on their rights and potential claims.

Contact Information

For further questions or to discuss potential representation, investors can contact Kessler Topaz Meltzer & Check, LLP directly. Details for inquiries include:
Attorney: Jonathan Naji, Esq.
Phone: (484) 270-1453
Email: [email protected]
Address: 280 King of Prussia Road, Radnor, PA 19087

Timely action is crucial, as the December 26 deadline looms. Investors are urged to seek the assistance of legal counsel to understand the implications of these developments fully. Kessler Topaz continues to play a significant role in holding corporations accountable for transparency and ethical governance, providing a platform for investors seeking justice and recovery in securities litigation.

DexCom investors now face a pressing timeframe, and taking appropriate legal action is essential for safeguarding their interests as the class action progresses.